GERN - Geron - Stock Price & Dividends

Geron Corporation is a biopharmaceutical company that specializes in developing and commercializing innovative treatments for myeloid hematologic malignancies, a group of life-threatening blood cancers. The company's primary focus is on creating therapies that can effectively target and combat these complex diseases.

At the forefront of Geron's pipeline is imetelstat, a telomerase inhibitor that has shown promising results in Phase 3 clinical trials. This novel drug works by inhibiting the uncontrolled growth of malignant stem and progenitor cells, which are a hallmark of myeloid hematologic malignancies. By targeting these cells, imetelstat has the potential to revolutionize the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis, two devastating conditions that currently have limited treatment options.

With a rich history dating back to 1990, Geron Corporation has established itself as a leader in the biopharmaceutical industry. Headquartered in Foster City, California, the company has built a reputation for its commitment to innovation, scientific excellence, and patient-centric approach. For more information about Geron Corporation and its mission to transform the lives of patients with myeloid hematologic malignancies, visit their website at https://www.geron.com.